Correction of Anemia in Chronic Kidney Disease With Angelica sinensis Polysaccharide via Restoring EPO Production and Improving Iron Availability

Kaiping Wang, Jun Wu, Jingya Xu, Saisai Gu, Qiang Li, Peng Cao, Mingming Li, Yu Zhang, Fang ZengFrontiers in Pharmacology 2018 · DOI

TL;DR

This study investigates Angelica sinensis polysaccharide (ASP) as a novel treatment for anemia in chronic kidney disease (CKD). ASP was found to boost erythropoietin (EPO) production by stabilizing key proteins and reducing inflammation, while also improving iron availability, offering a promising alternative to current treatments.

What Problem Does This Paper Address?

Anemia is a common and serious complication for patients with chronic kidney disease (CKD). The primary cause is a deficiency in erythropoietin (EPO), a hormone crucial for red blood cell production. Current treatments, like erythropoiesis-stimulating agents (ESAs) and iron supplementation, have limitations, including potential side effects, variable efficacy, and resistance in some patients. This creates a need for safer and more effective therapeutic strategies. This paper aims to explore the potential of Angelica sinensis polysaccharide (ASP), a component of a traditional Chinese herb, to address anemia in CKD by investigating its mechanisms of action.

Methods

The researchers employed a multi-pronged approach:

  • In vitro studies: They used Hep3B cells, a human hepatoma cell line commonly used to study EPO production under hypoxic conditions. They investigated how ASP affected the hypoxia-inducible factor (HIF) pathway, specifically HIF-1α and HIF-2α protein stability and EPO gene expression, under both normal and hypoxic conditions. They also examined ASP's effect on EPO inhibition induced by pro-inflammatory cytokines like TNF-α and IL-1β, focusing on the roles of GATA2 and NF-κB transcription factors.
  • In vivo studies: A rat model of CKD was established by feeding rats adenine, which induces kidney damage and anemia. These rats were then treated with ASP (at two different doses), recombinant human EPO (rhEPO) as a positive control, or a vehicle. The study monitored various parameters including kidney function (BUN, Scr), hematological markers (hemoglobin, RBC, WBC), spleen index, and pro-inflammatory cytokine levels in kidney and spleen.
  • Molecular analyses: Techniques like Western blotting were used to measure protein levels (HIF-1α, HIF-2α, NF-κB, GATA2, JAK2, STAT5, PI3K, Akt, ferritin, ferroportin, p-STAT3, p-SMAD1/5/8). Quantitative real-time PCR (qRT-PCR) was employed to assess mRNA expression (EPO, HIF-1α, HIF-2α, GATA2, NF-κB, PHD1/2/3, VEGFa, EPOR, Bcl-xL, Fam132b, TfR1, DMT1, hepcidin). Immunofluorescence staining was used to visualize NF-κB nuclear translocation.
  • Iron metabolism analysis: Serum iron levels and iron content in the spleen and liver were measured.

Datasets

Not discussed in the paper. The study utilized cell lines (Hep3B) and an animal model (adenine-induced CKD rats) for their experiments.

Key Insights and Ideas

  • ASP stabilizes HIF-2α: Under hypoxic conditions, ASP significantly increased the protein levels of HIF-1α and HIF-2α by preventing their degradation, rather than increasing their synthesis. This stabilization is key to boosting EPO production.
  • ASP counteracts inflammatory EPO suppression: Pro-inflammatory cytokines like TNF-α and IL-1β normally inhibit EPO production by activating GATA2 and NF-κB. ASP effectively blocked this activation, restoring EPO production even in the presence of these inflammatory signals.
  • ASP improves kidney function and reduces inflammation in CKD: In the rat model, ASP treatment not only corrected anemia but also significantly reduced markers of kidney damage (BUN, Scr) and systemic inflammation (WBC count, pro-inflammatory cytokine mRNA).
  • ASP enhances EPO signaling cascade: Beyond boosting EPO production, ASP also appeared to improve the responsiveness of bone marrow cells to EPO by increasing EPOR expression and activating downstream signaling pathways (JAK2/STAT5, PI3K/Akt), which are crucial for red blood cell maturation and survival.
  • ASP mobilizes iron stores: A critical finding is ASP's ability to suppress hepcidin, a hormone that blocks iron release. This leads to increased iron availability for hemoglobin synthesis by enhancing ferroportin expression and reducing ferritin, thereby addressing iron deficiency often seen in CKD anemia.

Key Results

  • In vitro: ASP treatment increased HIF-1α and HIF-2α protein levels in Hep3B cells under hypoxia. It also significantly boosted EPO mRNA expression and reversed the inhibitory effects of TNF-α and IL-1β on EPO production.
  • In vivo (CKD rats):
    • ASP treatment significantly reduced BUN and Scr levels, indicating improved kidney function.
  • ASP corrected anemia, leading to significantly higher hemoglobin and RBC levels compared to untreated CKD rats.
  • ASP treatment reduced spleen index and WBC counts, indicating reduced inflammation.
  • ASP administration increased serum EPO levels and EPO mRNA expression in both kidney and liver.
  • ASP treatment restored EPOR mRNA levels and activated downstream signaling pathways (JAK2/STAT5, PI3K/Akt) in bone marrow cells.
  • ASP increased the expression of genes promoting red blood cell survival (Bcl-xL) and iron uptake (TfR1, Fam132b).
  • ASP significantly increased serum iron levels while decreasing iron content in the spleen and liver.
  • ASP suppressed hepatic hepcidin mRNA expression and reduced p-STAT3 and p-SMAD1/5/8 levels.

Limitations and Future Work

  • Polysaccharide absorption: The authors acknowledge that the intestinal absorption of polysaccharides can be a concern due to their high molecular weight. However, they cite their previous work indicating that ASP can be absorbed via endocytosis.
  • VEGFa increase: While ASP increased VEGFa (a HIF-1α target gene involved in angiogenesis), the levels did not exceed normal ranges, and the overall effect on kidney function was ameliorative, suggesting this was not a detrimental side effect.
  • Future Directions: The study suggests that ASP's ability to enhance endogenous EPO production and improve iron availability could make it a valuable alternative or adjunctive therapy for CKD anemia. Further clinical trials would be necessary to confirm these findings in human patients. The potential for ASP to reduce the need for intravenous iron supplementation and improve the efficacy of ESAs is also highlighted.

Summary updated

Abstract

Given the limited efficacy and potential disadvantages of erythropoiesis-stimulating agents (ESAs) in treating anemia of chronic kidney disease (CKD), the development of better alternative therapies has become a priority. The primary purpose of this study is to investigate the effects of <i>Angelica sinensis</i> polysaccharide (ASP) and its underlying mechanism in the treatment of renal anemia. In the present study, we found that ASP could enhance hypoxic induction of EPO in Hep3B cells, with a mechanism that involved the stabilization of HIF-2α protein. In parallel, ASP rescued the inhibition of EPO, induced by proinflammatory factor TNF-α through blocking GATA2 and NF-κB activation. In a rat model of adenine-induced anemia of CKD, oral administration of ASP corrected anemia and alleviated renal damage and inflammation. By increasing the accumulation of HIF-2α protein and reducing the expression of NF-κB and GATA2 as well as pro-inflammatory cytokines, ASP stimulated both renal and hepatic EPO production, and resulted in an elevation of serum EPO. The restoration of EPO production and EPOR mRNA expression with ASP treatment activated EPOR downstream JAK2/STAT5 and PI3K/Akt signaling, induced their target genes, such as Bcl-xL, Fam132b and Tfrc, and increased Bcl-2/Bax ratio in bone marrow-derived mononuclear cells of CKD rats. Furthermore, we found that ASP suppressed hepatic hepcidin expression, mobilized iron from spleen and liver and increased serum iron. These findings demonstrate that ASP elicits anti-anemic action by restoring EPO production and improving iron availability in the setting of CKD in rats.
BibTeX
@inproceedings{wang2018correction,
  author = {Kaiping Wang and Jun Wu and Jingya Xu and Saisai Gu and Qiang Li and Peng Cao and Mingming Li and Yu Zhang and Fang Zeng},
  title = {{Correction of Anemia in Chronic Kidney Disease With Angelica sinensis Polysaccharide via Restoring EPO Production and Improving Iron Availability}},
  booktitle = {Frontiers in Pharmacology},
  year = {2018},
  doi = {10.3389/fphar.2018.00803},
}
Figure